NAMSA announces acquisition of Medvance

NAMSA, the world's leading medical research organization, is pleased to announce the acquisition of Medvance Ltd., a clinical research and resourcing organization located in Yorkshire, England.

The addition of Medvance expands NAMSA's MRO™ Approach to consulting and testing, adding dedicated support across the UK and continental Europe to NAMSA's already successful global footprint in the US, Germany, France and China. NAMSA supports clients through all product development phases, from regulatory knowledge through non-clinical and clinical research and even postmarket products and services. By combining the two companies, NAMSA has experts in nearly every therapeutic area to accelerate product development, market approval and extend market acceptance in all major markets around the globe.

"NAMSA is pleased to now be able to offer Medvance's regulatory, clinical and resourcing services along with our world-class expertise in R&D, biocompatibility and clinical research," said John Gorski, NAMSA's President and CEO. "Having experts across even more geographies will help clients deliver their products even more effectively to the physicians and patients around the world who need them most. This acquisition further demonstrates NAMSA's commitment to support our clients where and when they need it most."

"Medvance clients will benefit from NAMSA's deep expertise in biostatistics as well as their material scientists and biocompatibility experts," said Medvance CEO Janette Benaddi. "In addition, NAMSA's strength and relationships offer clients more insight into the US, Japan and China."

Medvance will hereafter be referred to as NAMSA Medvance. Janette Benaddi, Medvance CEO, will remain part of the new NAMSA Medvance in a key executive role.